Eli Lilly's Eloralintide and Tirzepatide Combo Delivers Up to 23.3% Weight Loss in Phase 2, Beating Tirzepatide Alone

SentiSense · Published Sep 29, 2026, 2:16 PM ET · Updated Sep 30, 2026, 1:57 PM ET

Eli Lilly said a combination of its experimental amylin drug eloralintide with tirzepatide produced up to 23.3% average weight loss in a 48-week Phase...